<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772157</url>
  </required_header>
  <id_info>
    <org_study_id>SEIGE</org_study_id>
    <nct_id>NCT04772157</nct_id>
  </id_info>
  <brief_title>Safe Emergency Department dIscharGe Rate (SEIGE)</brief_title>
  <acronym>SEIGE</acronym>
  <official_title>Safe Emergency Department dIscharGe Rate (SEIGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hennepin Healthcare Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Healthineers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hennepin Healthcare Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Siemens POC High Sensitivity Troponin-I Test System is an in vitro diagnostic test for&#xD;
      the quantitative measurement of cardiac troponin I (cTn-I) in fresh human capillary&#xD;
      (fingerstick) whole blood, and lithium-heparinized venous whole blood or plasma, to be used&#xD;
      by healthcare professionals at the point of care (POC) as well as in the clinical laboratory.&#xD;
&#xD;
      The Siemens POC High Sensitivity Troponin-I Test System is to be used as an aid in the&#xD;
      diagnosis of myocardial infarction (MI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study purpose/objective:&#xD;
&#xD;
        -  Evaluate the clinical performance of the Siemens POC HS cTn-I test system for the&#xD;
           diagnosis and rule out of AMI in patients presenting to the emergency department in whom&#xD;
           serial cTnI measurements are obtained on clinical indication.&#xD;
&#xD;
        -  Correlate the blood and plasma outcomes on the Siemens POC HS cTn-I test system as&#xD;
           function of the corresponding hematocrit (Hct) values.&#xD;
&#xD;
      Hypothesis: The Siemens POC HS cTn-I Test System will offer an excellent diagnostic&#xD;
      performance for acute myocardial injury and acute myocardial infarction, as well as expedite&#xD;
      the risk stratification of patients for early discharge from the emergency department.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Anticipated">October 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the incidence of undetectable(&lt;LoD), measurable (LoD - 99th percentile), and increased (&gt;99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System</measure>
    <time_frame>Day 1</time_frame>
    <description>Examine the incidence of undetectable(&lt;LoD), measurable (LoD - 99th percentile), and increased (&gt;99th percentile) cTn concentrations for the Siemens POC HS cTn-I Test System in comparison to a high sensitivity cTnI assay (Abbott &amp; Siemens Healthineers) to determine the potential impact on positivity rate, defined by sex-specific 99th percentiles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine Concordance</measure>
    <time_frame>Day 1</time_frame>
    <description>Examine concordance (dis) between hs-cTnI in comparison to a high sensitivity (Abbott &amp; Siemens Healthineers) cTnI assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine the diagnostic performance for acute myocardial injury and acute myocardial infarction</measure>
    <time_frame>Day 1</time_frame>
    <description>Examine the diagnostic performance for a) acute myocardial injury and b) acute myocardial infarction based on various diagnostic strategies using hs-cTnI measurement(s), as follows:&#xD;
Single measurement strategies&#xD;
Limit of detection (LoD)&#xD;
Concentration threshold tailored to meet a clinical need: Derive an optimal rule-out ng/L cutoff for Siemens POC HS cTn-I Test System.&#xD;
Accelerated serial sampling (0/2h protocol)&#xD;
Using the both sex-specific and overall 99th percentiles&#xD;
Delta (absolute concentration serial change value, 0-2h) analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs</measure>
    <time_frame>Day 1</time_frame>
    <description>Describe the incidence, clinical characteristics and outcomes of patients with and without hs-cTnI increases above the sex-specific 99th percentile URLs, including patients categorized with acute myocardial injury and acute myocardial infarction, including type 1 and 2 myocardial infarction following the 4th Universal Definition of Myocardial Infarction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact on the incidence of myocardial injury and myocardial infarction diagnoses.</measure>
    <time_frame>Day 1</time_frame>
    <description>Examine the potential impact on the incidence of myocardial injury and myocardial infarction diagnoses using hs-cTnI upon clinical practice implementation with a comparison to the hospital's final ICD-10 code diagnosis of type 1 and type 2 MIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to 30 days</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>up to 30 days</time_frame>
    <description>death due to cardiac reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjudicated index acute myocardial infarction according to 4th UDMI</measure>
    <time_frame>on admission</time_frame>
    <description>acute myocardial infarction, including sub-types following the Fourth Universal Definition of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Outcome - MACE</measure>
    <time_frame>30 days</time_frame>
    <description>Major Adverse Cardiovascular Event - cardiac death, myocardial infarction, revascularization, congestive heart failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Study population: Prospective, observational cohort study of consecutives patients (goal, 1000 patients over 4 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Troponin Testing</intervention_name>
    <description>Lithium heparin whole blood and plasma samples will be measured with Siemens POC High Sensitivity Troponin-I Test System.</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and plasma tested on the Siemens POC HS cTn-I Analyzer&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients (goal, 1000 patients over 4 months) presenting to the emergency&#xD;
        department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin&#xD;
        Healthcare / Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out&#xD;
        acute myocardial infarction.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Presents to the ED, or ambulatory care center equivalent, with signs or symptoms&#xD;
             suspicious of a possible ACS event.&#xD;
&#xD;
          2. Baseline cTn-I measurement and one additional cTn-I measurement at two hours after the&#xD;
             first measurement.&#xD;
&#xD;
          3. At least one 12-lead electrocardiogram&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Less than 21 years old&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Trauma&#xD;
&#xD;
          4. Declines to participate or has indicated that their blood/ medical information cannot&#xD;
             be used for investigational purposes&#xD;
&#xD;
          5. Did not present through the ED&#xD;
&#xD;
          6. Transferred from an outside hospital or clinic.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fred S Apple, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin Healthcare Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen M Schulz, DC</last_name>
    <phone>612-873-6893</phone>
    <email>kschulz@hhrinstitute.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hennepin Healthcare Research Institute / Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen M Schulz, DC</last_name>
      <phone>612-873-6893</phone>
      <email>kschulz@hhrinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Fred S Apple, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Troponin</keyword>
  <keyword>acute myocardial injury</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>Siemens POC</keyword>
  <keyword>Siemens POC Atellica® VTLi</keyword>
  <keyword>Siemens POC HS cTn-I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

